Enlight is a Boston-based company established in partnership with major pharmaceutical companies to develop breakthrough innovations that will fundamentally alter drug discovery and development.

Enlight’s Immersive Health initiative is advancing patient-centric technologies and platforms that may impact all aspects of the connected health ecosystem from patient engagement and experience, to patient-focused research and development. Enlight provides a mechanism through which our strategic partners can collaboratively support the rapid and tailored development of these high impact technologies.

Enlight's team also includes leading drug developers and innovators, such as Dr. Frank Douglas, PureTech Ventures Senior Partner, former Chief Scientific Officer and Executive Vice President of Aventis; and Dr. Bennett Shapiro, PureTech Ventures Senior Partner, former Executive Vice President of Basic Research and Worldwide Licensing at Merck & Co., Inc.